Literature DB >> 16971660

High-dose chemotherapy for triple negative breast cancer.

U De Giorgi1, G Rosti2, L Frassineti3, B Kopf2, N Giovannini3, F Zumaglini2, M Marangolo2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16971660     DOI： 10.1093/annonc/mdl306

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

1.  Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.

Authors:  A VanderWalde; W Ye; P Frankel; D Asuncion; L Leong; T Luu; R Morgan; P Twardowski; M Koczywas; R Pezner; I B Paz; K Margolin; J Wong; J H Doroshow; S Forman; S Shibata; G Somlo
Journal:  Biol Blood Marrow Transplant       Date:  2012-02-02       Impact factor: 5.742

2.  Native MAG-1 antibody almost destroys human breast cancer xenografts.

Authors:  William G North; Roy H L Pang; Guohong Gao; Vincent A Memoli; Bernard F Cole
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

3.  Association between oral contraceptive use as a risk factor and triple-negative breast cancer: A systematic review and meta-analysis.

Authors:  Li Li; Yahua Zhong; Hongyan Zhang; Haijun Yu; Yong Huang; Zheng Li; Gaili Chen; Xinying Hua
Journal:  Mol Clin Oncol       Date:  2017-05-12

4.  Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment.

Authors:  Sydney Stern; Dongdong Liang; Linhao Li; Ritika Kurian; Caitlin Lynch; Srilatha Sakamuru; Scott Heyward; Junran Zhang; Kafayat Ajoke Kareem; Young Wook Chun; Ruili Huang; Menghang Xia; Charles C Hong; Fengtian Xue; Hongbing Wang
Journal:  JCI Insight       Date:  2022-06-22

5.  Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.

Authors:  M E Cazzaniga; I Vallini; E Montagna; D Amoroso; R Berardi; A Butera; K Cagossi; L Cavanna; M Ciccarese; S Cinieri; E Cretella; E De Conciliis; A Febbraro; F Ferraù; A Ferzi; A Baldelli; A Fontana; A R Gambaro; O Garrone; V Gebbia; D Generali; L Gianni; F Giovanardi; A Grassadonia; V Leonardi; P Marchetti; S Sarti; A Musolino; M Nicolini; C Putzu; F Riccardi; D Santini; S Saracchini; M G Sarobba; M G Schintu; G Scognamiglio; P Spadaro; C Taverniti; D Toniolo; P Tralongo; A Turletti; R Valenza; M R Valerio; P Vici; P Di Mauro; V Cogliati; S Capici; L Clivio; V Torri
Journal:  Breast Cancer Res Treat       Date:  2021-09-21       Impact factor: 4.872

6.  CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer.

Authors:  Ashwini Makhale; Devathri Nanayakkara; Prahlad Raninga; Kum Kum Khanna; Murugan Kalimutho
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

7.  CAPER as a therapeutic target for triple negative breast cancer.

Authors:  Mallory C Campbell; Laura Pontiggia; Ashley Y Russell; Roland Schwarting; Jeanette Camacho; Jean-Francois Jasmin; Isabelle Mercier
Journal:  Oncotarget       Date:  2018-07-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.